JP2025041725A5 - - Google Patents
Info
- Publication number
- JP2025041725A5 JP2025041725A5 JP2024221344A JP2024221344A JP2025041725A5 JP 2025041725 A5 JP2025041725 A5 JP 2025041725A5 JP 2024221344 A JP2024221344 A JP 2024221344A JP 2024221344 A JP2024221344 A JP 2024221344A JP 2025041725 A5 JP2025041725 A5 JP 2025041725A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- amino acid
- pharmaceutical composition
- seq
- set forth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018231948 | 2018-12-11 | ||
| JP2018231948 | 2018-12-11 | ||
| PCT/JP2019/048171 WO2020122034A1 (ja) | 2018-12-11 | 2019-12-10 | 抗体－薬物コンジュゲートとｐａｒｐ阻害剤の組み合わせ |
| JP2020560106A JP7608164B2 (ja) | 2018-12-11 | 2019-12-10 | 抗体－薬物コンジュゲートとｐａｒｐ阻害剤の組み合わせ |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020560106A Division JP7608164B2 (ja) | 2018-12-11 | 2019-12-10 | 抗体－薬物コンジュゲートとｐａｒｐ阻害剤の組み合わせ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025041725A JP2025041725A (ja) | 2025-03-26 |
| JP2025041725A5 true JP2025041725A5 (enExample) | 2025-10-08 |
Family
ID=71076370
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020560106A Active JP7608164B2 (ja) | 2018-12-11 | 2019-12-10 | 抗体－薬物コンジュゲートとｐａｒｐ阻害剤の組み合わせ |
| JP2024221344A Pending JP2025041725A (ja) | 2018-12-11 | 2024-12-18 | 抗体－薬物コンジュゲートとｐａｒｐ阻害剤の組み合わせ |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020560106A Active JP7608164B2 (ja) | 2018-12-11 | 2019-12-10 | 抗体－薬物コンジュゲートとｐａｒｐ阻害剤の組み合わせ |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220023436A1 (enExample) |
| EP (1) | EP3909580A4 (enExample) |
| JP (2) | JP7608164B2 (enExample) |
| KR (1) | KR20210102341A (enExample) |
| CN (1) | CN113271942A (enExample) |
| AU (1) | AU2019396895B2 (enExample) |
| BR (1) | BR112021011119A2 (enExample) |
| EA (1) | EA202191641A1 (enExample) |
| SG (1) | SG11202106248XA (enExample) |
| TW (1) | TW202034959A (enExample) |
| WO (1) | WO2020122034A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3142119A1 (en) * | 2019-05-29 | 2020-12-03 | Daiichi Sankyo Company, Limited | Dosage of an antibody-drug conjugate for treating cancer |
| EP4225314A1 (en) * | 2020-10-09 | 2023-08-16 | AstraZeneca UK Limited | Combination of antibody-drug conjugate and parp1 selective inhibitor |
| WO2022248268A1 (en) * | 2021-05-28 | 2022-12-01 | Adc Therapeutics Sa | Combination therapy |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
| WO2023089527A1 (en) | 2021-11-18 | 2023-05-25 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and parp1 selective inhibitor |
| CN119317447A (zh) | 2022-04-12 | 2025-01-14 | 米纳瓦生物技术公司 | 抗可变muc1*抗体及其用途 |
| EP4531927A1 (en) * | 2022-05-24 | 2025-04-09 | Daiichi Sankyo Company, Limited | Dosage regimen of an anti-cdh6 antibody-drug conjugate |
| CN120813389A (zh) * | 2023-03-14 | 2025-10-17 | 第一三共株式会社 | 抗cdh6抗体-药物缀合物和vegf抑制剂的组合 |
| CN120916791A (zh) * | 2023-03-31 | 2025-11-07 | 第一三共株式会社 | 抗CDH6抗体-药物缀合物与HIF-2α抑制剂的组合 |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| EP4495003A1 (en) | 2023-07-20 | 2025-01-22 | AIRBUS HELICOPTERS DEUTSCHLAND GmbH | An external cargo adapter for use with a rotorcraft |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
| WO2000061739A1 (fr) | 1999-04-09 | 2000-10-19 | Kyowa Hakko Kogyo Co., Ltd. | Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle |
| PL203326B1 (pl) | 1999-06-25 | 2009-09-30 | Genentech Inc | Przeciwciało, kompozycja farmaceutyczna, koniugat, izolowany kwas nukleinowy, wektor, komórka gospodarza i sposób wytwarzania przeciwciała |
| MXPA03002974A (es) | 2000-10-06 | 2004-05-05 | Kyowa Hakko Kogyo Kk | Celulas que producen composiciones de anticuerpo. |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| CA2647632C (en) | 2006-03-27 | 2017-06-27 | University Of Maryland Biotechnology Institute | Glycoprotein synthesis and remodeling by enzymatic transglycosylation |
| SI2716301T1 (sl) | 2007-02-16 | 2017-07-31 | Merrimack Pharmaceuticals, Inc. | Protitelesa proti ErbB3 in uporaba le-teh |
| CN104220603B (zh) | 2012-02-10 | 2017-06-06 | 马里兰大学，巴尔的摩 | 抗体及其Fc片段的化学酶法糖基化工程 |
| KR102237639B1 (ko) | 2012-10-11 | 2021-04-07 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 콘주게이트 |
| ES2782248T3 (es) | 2012-10-19 | 2020-09-11 | Daiichi Sankyo Co Ltd | Conjugado de anticuerpo y fármaco producido por la unión a través de un enlazador que tiene estructura hidrófila |
| IL320281A (en) * | 2013-12-25 | 2025-06-01 | Daiichi Sankyo Co Ltd | Anti-trop2 antibodies and methods for producing same |
| PH12020552271A1 (en) * | 2014-01-31 | 2022-05-02 | Daiichi Sankyo Co Ltd | Anti-her2 antibody-drug conjugate |
| JP2017114763A (ja) | 2014-03-26 | 2017-06-29 | 第一三共株式会社 | 抗ｃｄ９８抗体−薬物コンジュゲート |
| DK3129063T3 (da) | 2014-04-10 | 2021-04-06 | Daiichi Sankyo Co Ltd | Anti-her3-antistof-lægemiddelkonjugat |
| EP3130608B1 (en) | 2014-04-10 | 2019-09-04 | Daiichi Sankyo Co., Ltd. | (anti-her2 antibody)-drug conjugate |
| US10195175B2 (en) * | 2015-06-25 | 2019-02-05 | Immunomedics, Inc. | Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors |
| US11173213B2 (en) | 2015-06-29 | 2021-11-16 | Daiichi Sankyo Company, Limited | Method for selectively manufacturing antibody-drug conjugate |
| EP3572428A4 (en) * | 2017-01-17 | 2020-12-30 | Daiichi Sankyo Company, Limited | ANTI-BODY ANTI-GPR20 AND ANTI-BODY-DRUG CONJUGATE ANTI-GPR20 |
| TW202530271A (zh) | 2017-05-15 | 2025-08-01 | 日商第一三共股份有限公司 | 抗體－藥物結合物及其用途 |
| KR20250084239A (ko) | 2017-08-31 | 2025-06-10 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 콘주게이트의 개량 제조 방법 |
-
2019
- 2019-12-10 KR KR1020217021368A patent/KR20210102341A/ko active Pending
- 2019-12-10 WO PCT/JP2019/048171 patent/WO2020122034A1/ja not_active Ceased
- 2019-12-10 CN CN201980082698.7A patent/CN113271942A/zh active Pending
- 2019-12-10 AU AU2019396895A patent/AU2019396895B2/en active Active
- 2019-12-10 EP EP19895941.3A patent/EP3909580A4/en active Pending
- 2019-12-10 US US17/312,084 patent/US20220023436A1/en active Pending
- 2019-12-10 JP JP2020560106A patent/JP7608164B2/ja active Active
- 2019-12-10 EA EA202191641A patent/EA202191641A1/ru unknown
- 2019-12-10 BR BR112021011119A patent/BR112021011119A2/pt unknown
- 2019-12-10 SG SG11202106248XA patent/SG11202106248XA/en unknown
- 2019-12-10 TW TW108145171A patent/TW202034959A/zh unknown
-
2024
- 2024-12-18 JP JP2024221344A patent/JP2025041725A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025041725A5 (enExample) | ||
| JPWO2020122034A5 (enExample) | ||
| JP7608164B2 (ja) | 抗体－薬物コンジュゲートとｐａｒｐ阻害剤の組み合わせ | |
| JP2023070678A5 (enExample) | ||
| TWI865337B (zh) | 抗體-藥物結合物之有效的製造方法 | |
| JPWO2020031936A5 (enExample) | ||
| JP2020515578A5 (enExample) | ||
| JPWO2020130125A5 (enExample) | ||
| JP2022095908A5 (enExample) | ||
| JP2020019787A5 (enExample) | ||
| JP2019031565A5 (enExample) | ||
| JP2021063058A5 (enExample) | ||
| JP2024075668A (ja) | 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ | |
| JP2010535713A5 (enExample) | ||
| JPWO2022102695A5 (enExample) | ||
| CA3047359A1 (en) | Hdac inhibitors-based antibody drug conjugates (adcs) and use in therapy | |
| JP6425653B2 (ja) | 抗腫瘍剤及び抗腫瘍効果増強剤 | |
| JP2020500834A5 (enExample) | ||
| JPWO2022102634A5 (enExample) | ||
| JPWO2019230645A5 (enExample) | ||
| JP2011505371A5 (enExample) | ||
| JPWO2020040245A5 (enExample) | ||
| JPWO2021251459A5 (enExample) | ||
| JPWO2021260579A5 (enExample) | ||
| JPWO2021260580A5 (enExample) |